Nihon Chouzai Co

Nihon Chouzai Co FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Nihon Chouzai Co (3341.T) as of Oct 29, 2026 is -28.32 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 392.28 % — a change of -107.22% (lower).

FCF Conversion

-28.32 %

YoY

-107.22%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Nihon Chouzai Co is 2025 -28.32 % . FCF Conversion Rate (FCF/EBITDA) of Nihon Chouzai Co was 2024 392.28 % . It decreases by -107.22% lower compared to the previous year.

The Nihon Chouzai Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
170.53 JPY
Jan 1, 2019
202.53 JPY
Jan 1, 2020
103.94 JPY
Jan 1, 2021
132.39 JPY
Jan 1, 2022
315.84 JPY
Jan 1, 2023
-4.98 JPY
Jan 1, 2024
392.28 JPY
Jan 1, 2025
-28.32 JPY
The Nihon Chouzai Co FCF Conversion history
YEARFCF ConversionYoY
-28.32 %-107.22%
392.28 %-7,977.48%
-4.98 %-101.58%
315.84 %+138.57%
132.39 %+27.37%
103.94 %-48.68%
202.53 %+18.77%
170.53 %-135.81%
-476.26 %-346.99%
192.83 %-2,502.12%
-8.03 %-93.16%
-117.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nihon Chouzai Co Stock analysis

What does Nihon Chouzai Co do? Nihon Chouzai Co Ltd is a Japanese pharmaceutical company that was founded in 1970. It specializes in the development and sale of pharmaceutical products and has built an impressive track record in recent decades. The business model of Nihon Chouzai is based on the manufacturing and sale of high-quality drugs for various diseases such as diabetes, hypertension, cardiovascular diseases, and cancer treatments. In addition, the company also offers a wide range of medical devices such as blood pressure monitors and insulin pens for diabetics. Another important division of Nihon Chouzai is the provision of pharmacy services to individual customers. The history of Nihon Chouzai began in the 1970s when the Japanese government launched a campaign to promote healthcare. The company recognized the importance of this campaign and started manufacturing quality drugs that were affordable for the general population. Since then, Nihon Chouzai has continuously invested in research and development to improve disease treatment. The company has also formed partnerships with other leading pharmaceutical companies worldwide to develop new medical technologies and treatment methods. In recent years, Nihon Chouzai has also conducted a number of acquisitions and mergers to expand its business. One of the most significant acquisitions was the acquisition of Daiichi Sankyo, a leading Japanese pharmaceutical company. In terms of products, Nihon Chouzai offers a wide range of drugs that cater to the needs of different patient groups. These include innovative cancer therapies, diabetes medications, lipid-lowering drugs, and blood pressure medications. Nihon Chouzai is also a leading provider of medical devices and consumables. The key products in this area are blood glucose monitors for diabetics, acupuncture needles for pain relief, and optical fiber endoscopic devices for gastroenterology. In addition to its consumer product offerings, Nihon Chouzai also provides specialized pharmacy services to individual customers. These services include setting up remote pharmacies for rural areas, conducting training for pharmacy technicians, and providing medical expertise to the public. Overall, Nihon Chouzai has established itself as a successful pharmaceutical and medical technology company that operates both in Japan and globally. The company relies on innovative research and development to meet the expectations of patients and doctors and improve healthcare. Nihon Chouzai Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nihon Chouzai Co stock

FCF Conversion Rate (FCF/EBITDA) of Nihon Chouzai Co is -28.32 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Nihon Chouzai Co changed from 392.28 % to -28.32 %, representing a -107.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Nihon Chouzai Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Nihon Chouzai Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nihon Chouzai Co

All Key Metrics — Nihon Chouzai Co